Sangamo Therapeutics Inc (NASDAQ:SGMO) Expected to Post Earnings of -$0.31 Per Share

Share on StockTwits

Wall Street brokerages expect Sangamo Therapeutics Inc (NASDAQ:SGMO) to announce earnings per share of ($0.31) for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Sangamo Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.27) and the lowest estimate coming in at ($0.42). Sangamo Therapeutics posted earnings of ($0.18) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 72.2%. The firm is scheduled to issue its next earnings report on Thursday, February 27th.

On average, analysts expect that Sangamo Therapeutics will report full-year earnings of ($1.20) per share for the current fiscal year, with EPS estimates ranging from ($1.32) to ($1.15). For the next financial year, analysts anticipate that the business will post earnings of ($1.13) per share, with EPS estimates ranging from ($1.54) to $0.10. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Sangamo Therapeutics.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.10. Sangamo Therapeutics had a negative net margin of 159.12% and a negative return on equity of 30.33%. The firm had revenue of $21.96 million during the quarter, compared to analyst estimates of $12.16 million. During the same quarter in the prior year, the firm posted ($0.13) earnings per share. Sangamo Therapeutics’s quarterly revenue was down 6.8% on a year-over-year basis.

SGMO has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Sangamo Therapeutics from a “hold” rating to a “strong-buy” rating and set a $9.50 price objective for the company in a report on Wednesday. BidaskClub lowered shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 13th. Wedbush reissued a “hold” rating and issued a $11.00 price objective on shares of Sangamo Therapeutics in a report on Wednesday, December 18th. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Sangamo Therapeutics in a report on Monday, December 23rd. Finally, Cowen reissued a “buy” rating on shares of Sangamo Therapeutics in a report on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $12.17.

Shares of SGMO traded down $0.48 during mid-day trading on Tuesday, reaching $8.37. The stock had a trading volume of 1,684,601 shares, compared to its average volume of 1,414,894. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.10. Sangamo Therapeutics has a 52-week low of $6.26 and a 52-week high of $13.91. The business’s fifty day moving average is $9.06 and its 200 day moving average is $10.05.

A number of hedge funds have recently made changes to their positions in the business. Prudential Financial Inc. boosted its stake in Sangamo Therapeutics by 10.1% during the second quarter. Prudential Financial Inc. now owns 13,878 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 1,270 shares during the period. Oppenheimer Asset Management Inc. boosted its stake in Sangamo Therapeutics by 13.0% during the third quarter. Oppenheimer Asset Management Inc. now owns 15,866 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 1,831 shares during the period. Russell Investments Group Ltd. boosted its stake in Sangamo Therapeutics by 1.8% during the third quarter. Russell Investments Group Ltd. now owns 101,292 shares of the biopharmaceutical company’s stock worth $917,000 after buying an additional 1,833 shares during the period. Public Employees Retirement System of Ohio boosted its stake in Sangamo Therapeutics by 1.6% during the second quarter. Public Employees Retirement System of Ohio now owns 121,713 shares of the biopharmaceutical company’s stock worth $1,311,000 after buying an additional 1,888 shares during the period. Finally, HighTower Advisors LLC lifted its position in shares of Sangamo Therapeutics by 4.4% during the second quarter. HighTower Advisors LLC now owns 48,655 shares of the biopharmaceutical company’s stock worth $523,000 after purchasing an additional 2,050 shares in the last quarter. 70.84% of the stock is owned by institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

Further Reading: Municipal Bonds

Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.